FARMAKOLOGI MOLEKULER
PHASE II TRIAL OF SINGLE-AGENT
PHASE
II TRIAL (GSK1363089)
OF SINGLE-AGENT
FORETINIB
FORETINIB
(GSK1363089)
IN PATIENTS
WITH
RECURRENT OR
IN PATIENTS
WITH RECURRENT
OR
METASTATIC
SQUAMOUS
CELL CARCINOMA
METASTATIC
SQUAMOUS
CELL
CARCINOMA
OF THE
HEAD AND
NECK
OF THE HEAD AND NECK
Kelompok 2
Latar Belakang
Squamous Cell Carcinoma of the Head and
Neck (SCCHN) merupakan salah satu kanker
penyebab kematian, didiagnosa sekitar
650.000 jiwa/tahun di Amerika serikat
50.000 positif HCN
11.000 meninggal
Faktor resiko:
- Penggunaan alkohol
- Penggunaan tembakau (rokok)
VEGF
MET
(Mesenchymal
Ephithelial Transition)
Tumor angiogenesis
Foretinib
Reseptor Tyrosin Kinase:
- reseptor faktor pertumbuhan
(growth factor)
- reseptor sitokin
- reseptor insulin
Reseptor faktor pertumbuhan
1. EGF (epithelial growth factor)
2.
Target utama :
- MET/HGF (mesenchymal epithelial
transition)
- Vascular endothelial growth factor
receptor-2 (VEGFR2)